FASLODEX 500 mg dose was studied in the CONFIRM† Trial
*The FALCON Trial, which examined the efficacy and safety of FASLODEX (500 mg) vs anastrozole (1 mg), was a phase 3, randomized, double-blind, double-dummy, multicenter study of 462 postmenopausal women who had not previously been treated with endocrine therapy.1,2 All patients had locally advanced breast cancer or mBC.2 All patients tested ER+ and/or PgR+, and most (except 1 patient) tested HER2-negative.2
†The CONFIRM Trial was a randomized, double-blind, controlled phase 3 study of 736 postmenopausal women with advanced breast cancer (ABC) who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease.
References: 1. FASLODEX® (fulvestrant) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018. 2. Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997-3005.